Literature DB >> 10418796

Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications.

M B Holmes1, B E Sobel, D B Howard, D J Schneider.   

Abstract

Increased platelet reactivity is a descriptor of the risk of cardiovascular events in healthy men and in patients with overt coronary artery disease. We sought to determine if differential thresholds exist for activation of platelets with respect to alpha-granule degranulation and fibrinogen binding in healthy volunteers and in patients with acute coronary syndromes. We also sought to characterize the effect of aspirin on activation. Platelet activation was assessed with flow cytometry in whole blood anticoagulated with corn trypsin inhibitor and incubated with fluorescein isothiocyanate conjugated fibrinogen (to define activation of glycoprotein IIb-IIIa), a phycoerythrin conjugated antibody to P-selectin (a marker of alpha-granule degranulation), and selected concentrations of adenosine diphosphate (ADP) or thrombin receptor agonist peptide. ADP-induced fibrinogen binding was found to be a low threshold activation event (40% of platelets bound fibrinogen in response to 0.2 microM ADP). Alpha-granule degranulation was a higher threshold event (33% of platelets expressed P-selectin in response to 1.0 microM ADP). Intra- and interindividual variability were most apparent with low concentrations of agonist (0.2 microM ADP). Patients with acute coronary syndromes (on aspirin) had significantly increased P-selectin expression in response to ADP compared with healthy subjects (on aspirin), but no difference in ADP-induced fibrinogen binding was observed. Daily ingestion of 325 mg of aspirin had no effect on either P-selectin expression or fibrinogen binding in healthy subjects. Analysis of platelet reactivity with flow cytometry characterizes activation with respect to specific components of the process and should facilitate development and optimal titration of antiplatelet therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10418796     DOI: 10.1016/s0049-3848(99)00019-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of anti-thrombotic therapy.

Authors:  S S Kabbani; M W Watkins; P A Holoch; E F Terrien; B E Sobel; D J Schneider
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

Review 2.  The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome.

Authors:  E J Topol
Journal:  Clin Cardiol       Date:  2000-11       Impact factor: 2.882

3.  The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro.

Authors:  Friederike K Keating; David J Schneider
Journal:  J Thromb Thrombolysis       Date:  2008-06-25       Impact factor: 2.300

4.  Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention.

Authors:  Atul Aggarwal; Burton E Sobel; David J Schneider
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

5.  Modulation of P-selection and platelet aggregation in chronic periodontitis: A clinical study.

Authors:  Ramesh Perumal; Maheashwari Rajendran; Malathi Krishnamurthy; Kiran Kumar Ganji; Sunil Dattuji Pendor
Journal:  J Indian Soc Periodontol       Date:  2014-05

6.  Attenuation of Thrombosis by Crude Rice (Oryza sativa) Bran Policosanol Extract: Ex Vivo Platelet Aggregation and Serum Levels of Arachidonic Acid Metabolites.

Authors:  Wai-Teng Wong; Maznah Ismail; Eusni Rahayu Mohd Tohit; Rasedee Abdullah; Yi-Da Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-05       Impact factor: 2.629

7.  Increased platelet expression of FcGammaRIIa and its potential impact on platelet reactivity in patients with end stage renal disease.

Authors:  Feliciano A Serrano; Mohamed El-Shahawy; Richard J Solomon; Burton E Sobel; David J Schneider
Journal:  Thromb J       Date:  2007-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.